tetano
Editor, Senior Moderator
Vaccine. 2016 Aug 26. pii: S0264-410X(16)30762-9. doi: 10.1016/j.vaccine.2016.08.066. [Epub ahead of print]
[h=1]Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.[/h] Cheng T[SUP]1[/SUP], Wang X[SUP]1[/SUP], Song Y[SUP]1[/SUP], Tang X[SUP]1[/SUP], Zhang C[SUP]1[/SUP], Zhang H[SUP]1[/SUP], Jin X[SUP]2[/SUP], Zhou D[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Highly pathogenic avian H5N1 viruses may give rise to the next influenza pandemic due to their reassortment and mutation of the genome. Vaccine against this virus is important for coping with its potential threat. Chimpanzee adenovirus (Ad) vectors are a novel type of vaccine vectors that share the advantages of human serotype Ad vectors but without being affected by pre-existing human neutralizing antibody to the vaccine vector. Based on a replication-deficient chimpanzee Ad vector, AdC7, we generated a novel H5N1 vaccine candidate AdC7-H5HA that expresses H5N1 Hemagglutinin(HA). When tested in mice, the vaccine significantly reduced the virus load and pathological lesions in the lung tissues, and conferred complete protection against lethal challenge by a homologous virus. Mechanistically, the AdC7-H5HA vaccine can induce both HA-specific humoral and cell-mediated immune responses in mice. Also, sera transfer experiments demonstrated that neutralizing antibodies alone could provide protection. In conclusion, our results show that chimpanzee Ad vector expressing influenza virus HA may represent a promising vaccine candidate for H5N1 viruses and other influenza virus subtypes.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] AdC7; H5N1; Immune responses; Influenza; Vaccine
PMID: 27576071 DOI: 10.1016/j.vaccine.2016.08.066
[PubMed - as supplied by publisher]
[h=1]Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.[/h] Cheng T[SUP]1[/SUP], Wang X[SUP]1[/SUP], Song Y[SUP]1[/SUP], Tang X[SUP]1[/SUP], Zhang C[SUP]1[/SUP], Zhang H[SUP]1[/SUP], Jin X[SUP]2[/SUP], Zhou D[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Highly pathogenic avian H5N1 viruses may give rise to the next influenza pandemic due to their reassortment and mutation of the genome. Vaccine against this virus is important for coping with its potential threat. Chimpanzee adenovirus (Ad) vectors are a novel type of vaccine vectors that share the advantages of human serotype Ad vectors but without being affected by pre-existing human neutralizing antibody to the vaccine vector. Based on a replication-deficient chimpanzee Ad vector, AdC7, we generated a novel H5N1 vaccine candidate AdC7-H5HA that expresses H5N1 Hemagglutinin(HA). When tested in mice, the vaccine significantly reduced the virus load and pathological lesions in the lung tissues, and conferred complete protection against lethal challenge by a homologous virus. Mechanistically, the AdC7-H5HA vaccine can induce both HA-specific humoral and cell-mediated immune responses in mice. Also, sera transfer experiments demonstrated that neutralizing antibodies alone could provide protection. In conclusion, our results show that chimpanzee Ad vector expressing influenza virus HA may represent a promising vaccine candidate for H5N1 viruses and other influenza virus subtypes.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] AdC7; H5N1; Immune responses; Influenza; Vaccine
PMID: 27576071 DOI: 10.1016/j.vaccine.2016.08.066
[PubMed - as supplied by publisher]